From Financial Modeling Prep: 2025-04-16 10:07:00

Abbott Laboratories, listed as NYSE:ABT, reported an EPS of $1.09, beating estimates and showing improvement from the previous year. The company’s revenue of $10.36 billion slightly missed estimates but reaffirmed its annual guidance with strong growth projections. Abbott’s financial health is solid, with a P/E ratio of around 17.08 and a debt-to-equity ratio of about 0.32, indicating moderate debt levels and strong market valuation.



Read more at Financial Modeling Prep:: Abbott Laboratories’ Strong First Quarter Performa…